nad has been researched along with gne-618 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belmont, LD; DelNagro, C; Durieux, JK; Elkins, K; Jackson, PK; Kwong, M; Lee, L; Liang, X; Liederer, BM; O'Brien, T; Oeh, J; Sampath, D; Tremayne, J; Xiao, Y; Yang, LX | 1 |
1 other study(ies) available for nad and gne-618
| Article | Year |
|---|---|
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Heterografts; Humans; Lung Neoplasms; Mice, Nude; NAD; Pentosyltransferases; Pyrazoles; Sulfones | 2013 |